Rare Diseases: Medical Treatments
Commons · Question 29295 · Tabled 11 Sep 2026 · Department of Health and Social Care · Official record
Answered 22 Sep 2026
Question
Asked by Lee Dillon
To ask the Secretary of State for Health and Social Care, what assessment she has made of whether the National Institute for Health and Care Excellence's cost-effectiveness methodology adequately reflects the particular circumstances of medicines for rare
Answer
Answered by James Frith, 22 Sep 2026
The National Institute for Health and Care Excellence (NICE) has been able to recommend many medicines licensed for the treatment of rare diseases for use on the National Health Service where companies engage constructively in the process and price their ...